These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30986117)

  • 1. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
    Lieu C; Kennedy EB; Bergsland E; Berlin J; George TJ; Gill S; Gold PJ; Hantel A; Jones L; Mahmoud N; Meyerhardt J; Morris AM; Ruíz-García E; You YN; Baxter N
    J Clin Oncol; 2019 Jun; 37(16):1436-1447. PubMed ID: 30986117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
    Sobrero A; Grothey A; Iveson T; Labianca R; Yoshino T; Taieb J; Maughan T; Buyse M; André T; Meyerhardt J; Shields AF; Souglakos I; Douillard JY; Cervantes A
    Ann Oncol; 2018 May; 29(5):1099-1107. PubMed ID: 29438451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new prognostic and predictive tool for shared decision making in stage III colon cancer.
    Sobrero AF; Puccini A; Shi Q; Grothey A; Andrè T; Shields AF; Souglakos I; Yoshino T; Iveson T; Ceppi M; Bruzzi P
    Eur J Cancer; 2020 Oct; 138():182-188. PubMed ID: 32892120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
    Margalit O; Mamtani R; Yang YX; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Eur J Cancer; 2018 Jun; 96():105-110. PubMed ID: 29698932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
    J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?
    Formica V; Zaniboni A; Loupakis F; Roselli M
    Int J Cancer; 2018 Nov; 143(10):2342-2350. PubMed ID: 29873066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating IDEA to Practice and Beyond: Managing Stage II and III Colon Cancer.
    Gill S; Meyerhardt JA; Arun M; Veenstra CM
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():226-235. PubMed ID: 31099666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
    Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration.
    Paolo M Cruz J; George C Pales C; Min Kim K; Wan Kim Y
    J BUON; 2018; 23(3):568-573. PubMed ID: 30003720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
    Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR
    JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
    Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
    Shroff RT; Kennedy EB; Bachini M; Bekaii-Saab T; Crane C; Edeline J; El-Khoueiry A; Feng M; Katz MHG; Primrose J; Soares HP; Valle J; Maithel SK
    J Clin Oncol; 2019 Apr; 37(12):1015-1027. PubMed ID: 30856044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.
    Tang M; Price TJ; Shapiro J; Gibbs P; Haller DG; Arnold D; Peeters M; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):339-349. PubMed ID: 29478352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
    Shah MA; Renfro LA; Allegra CJ; André T; de Gramont A; Schmoll HJ; Haller DG; Alberts SR; Yothers G; Sargent DJ
    J Clin Oncol; 2016 Mar; 34(8):843-53. PubMed ID: 26811529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis.
    Kuang Z; Wang J; Liu K; Wu J; Li J
    Int J Surg; 2024 May; 110(5):3030-3038. PubMed ID: 38349218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
    Brungs D; Aghmesheh M; de Souza P; Carolan M; Clingan P; Rose J; Ranson M
    Clin Colorectal Cancer; 2018 Sep; 17(3):e549-e555. PubMed ID: 29861156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
    J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
    Kris MG; Gaspar LE; Chaft JE; Kennedy EB; Azzoli CG; Ellis PM; Lin SH; Pass HI; Seth R; Shepherd FA; Spigel DR; Strawn JR; Ung YC; Weyant M
    J Clin Oncol; 2017 Sep; 35(25):2960-2974. PubMed ID: 28437162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study.
    van den Berg I; van de Weerd S; Roodhart JML; Vink GR; van den Braak RRJC; Jimenez CR; Elias SG; van Vliet D; Koelink M; Hong E; van Grevenstein WMU; van Oijen MGH; Beets-Tan RGH; van Krieken JHJM; IJzermans JNM; Medema JP; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):776. PubMed ID: 32811457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.